Option Therapeutics

The company's lead candidate was an oral small-molecule prodrug designed to be a selective adenosine A2A receptor antagonist. It was administered prior to therapeutic intermittent hypoxia sessions to enhance respiratory motor plasticity. The approach aimed to amplify the body's natural neural adaptive response to low-oxygen conditions in patients with chronic spinal cord injuries, specifically targeting cervical injuries that impair breathing. The underlying mechanism was based on decades of preclinical research demonstrating that A2A receptor blockade can potentiate the functional benefits of intermittent hypoxia on phrenic motor output.

In December 2021, the company announced positive results from a randomized, double-blind, placebo-controlled Phase 2a clinical trial in patients with chronic tetraplegia. The trial met its primary endpoint, demonstrating that the lead candidate significantly increased minute ventilation during breathing trials compared to placebo when combined with a single session of acute intermittent hypoxia. The study was conducted at multiple spinal cord injury research centers across the United States and supported in part by National Institutes of Health grants.

The company targeted individuals with chronic cervical spinal cord injury resulting in tetraplegia and compromised respiratory function. This population frequently relies on mechanical ventilation or experiences significant breathing impairments that increase mortality risk and reduce quality of life. The company specifically focused on patients who were beyond the acute injury phase — typically more than one year post-injury — where spontaneous neurological recovery has plateaued and no approved drug therapies exist to improve respiratory function.

The scientific underpinnings of Option Therapeutics came from researchers at the University of Florida and the Malcom Randall VA Medical Center who had spent decades studying respiratory neuroplasticity after spinal cord injury. Their work on adenosine receptor modulation and acute intermittent hypoxia protocols provided the mechanistic rationale for the company's drug development program. Specific named principals at the company's operational level were not widely publicized, consistent with the firm's lean clinical-stage structure and limited public-facing presence.

As of mid-2026, no public updates regarding Option Therapeutics' corporate status or clinical development programs have appeared since the December 2021 Phase 2a data announcement. The company's website is no longer accessible, and no regulatory filings, partnership announcements, or acquisition disclosures are publicly available. The entity appears to have ceased operations or been dissolved. This pattern is common for single-asset biotech companies that complete an initial clinical readout but cannot secure follow-on financing for subsequent trials.